BioNTech SE (BNTX) stock
BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.26−1.60 (-1.89%)
Close on Nov 18, 2026Market cap $20.92BP/E –Yield –
BioNTech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was €280.90M. The highest annual figure on record is €13.25B in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €280.90M | – |
| FY2024 | Dec 31, 2024 | -€78.80M | -101.5% |
| FY2023 | Dec 31, 2023 | €5.12B | -61.3% |
| FY2022 | Dec 31, 2022 | €13.25B | +1638.2% |
| FY2021 | Dec 31, 2021 | €762.20M | – |
| FY2020 | Dec 31, 2020 | -€79.50M | – |
| FY2019 | Dec 31, 2019 | -€237.10M | – |
| FY2018 | Dec 31, 2018 | -€88.78M | – |
| FY2017 | Dec 31, 2017 | -€76.88M | – |
See a number that looks wrong?